DNTH Dianthus Therapeutics, Inc.

NASDAQ
$86.03

Dianthus Therapeutics, Inc. (DNTH) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.97 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.2% since its last earnings release on November 4, 2026.

Dianthus Therapeutics Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.97)
Rev est $800K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $84.10

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.